Skip to main content
. 2011 Aug 1;208(8):1695–1705. doi: 10.1084/jem.20102657

Figure 1.

Figure 1.

Phenotype of Flt3L-responsive CD45hiCD11c+MHC II+ cells in the steady-state mouse brain. (A and B) Flow cytometric dot plots of EYFP expression in brain leukocytes (A) and the splenocytes (B) of untreated (top) versus Flt3L-treated (bottom) CD11c-EYFP transgenic mice. Numbers indicate percentage of gated cells. Data are representative of three independent experiments. (C) Flow cytometric dot plots of CD45+ mononuclear cells in the brain of untreated (top) versus Flt3L-treated (bottom) nontransgenic C57BL/6 mice. Histograms show MHC II staining on the surface of DCs and microglia (MG) from the indicated gates. Data are representative of more than three independent experiments. (D) Bar graph shows quantification of m/chDCs and microglia 14 d after Flt3L treatment in B6 mice. Bars represent data from two pooled experiments, each with two brains. Error bars represent the mean ± SEM (n = 4; ***, P < 0.0001).